AUROPHARMA2023-04-012023-06-30 AUROPHARMA2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2023-06-30 AUROPHARMA2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524804 AUROPHARMA NOTLISTED Aurobindo Pharma Limited Equity 2023-04-01 2024-03-31 2023-08-12 2023-08-03 INR Millions First quarter 15:30:00 17:40:00 2023-08-12 2023-08-12 Not applicable Single segment Pharmaceutical Products 2023-04-01 2023-06-30 Unaudited Standalone 23908200000.00 948800000.00 24857000000.00 13752600000.00 155300000.00 -162500000.00 2360600000.00 315900000.00 596300000.00 3578400000.00 20596600000.00 4260400000.00 0.00 4260400000.00 1163000000.00 -82600000.00 1080400000.00 0.00 3180000000.00 240500000.00 61000000.00 179500000.00 0.00 3359500000.00 14700000.00 3374200000.00 3374200000.00 0.00 585900000.00 1 5.43 5.43 0.31 0.31 5.74 5.74 1. The above standalone financial results of Aurobindo Pharma Limited ( the Company ) have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. The above standalone financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 12, 2023. The results for the quarter ended June 30, 2023 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2023. 3. The Company operates in only one reportable segment viz., 'Pharmaceutical Products'. 4. The Board of Directors of the Company at its meeting held on June 17, 2022 had approved investment in GLS Pharma Limited (GLS). Consequently the Company entered into share subscription and purchase agreement and obtained control (51%) w.e.f August 17, 2022. Other Expenses 3578400000.00 Notes continued.......... 5. The Board of Directors of the Company at its meeting held on February 9, 2023 and April 01, 2023 approved the transfer of certain Active Pharmaceutical Ingredients (API) business units (Unit I, VIII, IX, XI,XIV, RC– 2, V and XVII) to its wholly owned subsidiary, Apitoria Pharma Private Limited (APPL) (formerly known as Auro Pharma India Private Limited) on a going concern basis by way of a slump sale w.e.f April 01, 2023 subject to certain conditions precedent including receipt of requisite approvals. The Company is co-ordinating with relevant regulatory agencies for formalities to be completed for the proposed transfer. Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 Non-Current Assets Held for Sale and Discontinued Operations , in the standalone financial results for all the periods have been suitably presented. Key financials information of discontinued Operations: (Rs. in Million) Particulars Quarter ended Year ended 30.06.2023 31.03.2023 30.06.2022 31.03.2023 Total Income 11,207.4 11,494.2 10,461.0 43,260.8 Total expenses 10,966.9 10,908.4 10,650.5 43,458.4 Profit/(loss) before tax 240.5 585.8 (189.5) (197.6) Total tax expense 61.0 122.9 (53.4) (47.0) Net profit/(loss) for the period 179.5 462.9 (136.1) (150.6) 6. The figures for the quarter ended March 31, 2023 are the balancing figures of the audited financials for the year ended March 31, 2023 and unaudited the year to date published results for the nine months ended December 31, 2022, which were subject to limited review by the statutory auditors. Re-measurement of defined benefit liability 19600000.00 19600000.00 4900000.00 0.00